# Calliditas Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calliditas-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Stockholm, Sweden
- Website: www.calliditas.se
- Total disclosed funding: $20M
- Latest round: Series C (Oct 3, 2013)
- Investors on record: 2

## About

Calliditas Therapeutics AB is a biopharmaceutical company focused on developing and marketing innovative therapeutics for rare diseases, particularly renal and hepatic conditions, enhancing treatment options for affected patients.Calliditas Therapeutics AB specializes in biopharmaceuticals, specifically targeting rare diseases. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Over its history, it has completed a total of 8 deals, with its most recent deal occurring on June 15, 2018. The company went public via an IPO raising USD 90.000 mn, which is also the total amount raised to date. The current CEO is Renee Aguiar-Lucander.Calliditas Therapeutics AB focuses on developing and marketing innovative therapeutics for rare diseases, primarily targeting renal and hepatic conditions. Their flagship products include TARPEYO® (budesonide) delayed release capsules and Kinpeygo®, both designed to address IgA nephropathy and other orphan indications. TARPEYO® aims to reduce proteinuria in patients suffering from this progressive kidney disease, while Kinpeygo® serves as an adjunct in the treatment of various hepatic disorders. These products are marketed primarily in North America and Europe, targeting healthcare providers, hospitals, and specialty pharmacies that cater to patients dealing with these challenging health issues.Calliditas Therapeutics generates revenue through the sale of its proprietary medications, specifically TARPEYO® and Kinpeygo®. In the most recent year of 2022, the company's revenue amounted to USD 79.64 mn with an EBITDA of USD -40.57 mn. The company’s transaction structure involves direct sales through partnerships with healthcare providers and pharmacies, ensuring distribution to end users based on prescriptions written by physicians for patients diagnosed with IgA nephropathy and related conditions.Calliditas Therapeutics plans to utilize the capital raised from its most recent IPO in June 2020, where it raised USD 90.000 mn, to support upcoming product launches and expand into new geographic markets. The company aims to develop additional therapeutics for renal diseases and anticipates releasing new products in the coming years. Specifically, Calliditas is targeting expansion into further markets in Europe and North America by 2025, enhancing its market presence and accessibility of its innovative treatments.

## Funding rounds

- Series C, Oct 3, 2013, $15M — Industrifonden, Investinor
- Series B, Jan 4, 2012, $5.1M — Industrifonden

## Investors

- Industrifonden (https://capitalatlas.ai/funds/industrifonden) — Series B, Series C
- Investinor (https://capitalatlas.ai/funds/investinor) — Series C